Delta-Fly Pharma Inc Is Granted Orphan Drug Designation By Us Food And Drug Administration For Dfp-10917
Delta-Fly Pharma, Inc.Announces That Dfp-10917, A Leading Pipeline Of The Company, Is Granted Orphan Drug Designation (Odd) By Us Food And Drug Administration (Fda) For The Treatment Of Acute Myeloid Leukemia (Aml).Be Given To Odd, Delta-Fly Pharma, Inc. Can Be Entitled To Seven Extra Years Of Marketing Exclusivity And Receive Some Benefits Such As R&D Rebate By Getting Approval.Dfp-10917 Is An Anti-Cancer Agent In Development For The Treatment Of Patients With Refractory/Relapsed Aml. A Phase 3 Clinical Study Has Been Underway At Md Anderson Cancer Center In Texas And Other Major Sites Of Hematologic Cancer Treatment In Usa. The Company Expects To Complete The Patients
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
